Background:  CTNNBIP1 (Catenin, beta interacting protein 1) binds to beta-catenin and prevents the interaction between beta-catenin and TCF transcription factor family members. It is a negative regulator of the Wnt signaling pathway.ICAT interacts directly with β-catenin and interferes with the Wnt signaling pathway. Specifically, ICAT prevents the interaction of β-catenin with TCF-4 and inhibits βcatenin–TCF-4-mediated transactivation. The negative regulatory effect of ICAT on the Wnt signaling pathway appears to inhibit tumor cell proliferation. ICAT also induces G2 arrest followed by cell death in colorectal tumor cells. The ectopic induction of ICAT inhibits the expression of βIII-Tubulin and thus neuronal differentiation in embryonal carcinoma P19 cells. Structural characteristics of ICAT include a 3-helix bundle and a C-terminal tail.

Description: Rabbit polyclonal to CTNNBIP1

Immunogen: KLH conjugated synthetic peptide derived from CTNNBIP1

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 9 kDa;

·Immunohistochemistry (Frozen/paraffin tissue section): 1/100-200;

·Immunocytochemistry: 1/100;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.